Coherus BioSciences (CHRS) Competitors $1.71 +0.01 (+0.59%) (As of 12/17/2024 05:56 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CHRS vs. IMNM, KROS, KURA, TYRA, CRON, ERAS, EOLS, RAPP, DNTH, and AUTLShould you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Immunome (IMNM), Keros Therapeutics (KROS), Kura Oncology (KURA), Tyra Biosciences (TYRA), Cronos Group (CRON), Erasca (ERAS), Evolus (EOLS), Rapport Therapeutics (RAPP), Dianthus Therapeutics (DNTH), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Coherus BioSciences vs. Immunome Keros Therapeutics Kura Oncology Tyra Biosciences Cronos Group Erasca Evolus Rapport Therapeutics Dianthus Therapeutics Autolus Therapeutics Immunome (NASDAQ:IMNM) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Does the MarketBeat Community believe in IMNM or CHRS? Coherus BioSciences received 416 more outperform votes than Immunome when rated by MarketBeat users. However, 73.81% of users gave Immunome an outperform vote while only 65.26% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformImmunomeOutperform Votes3173.81% Underperform Votes1126.19% Coherus BioSciencesOutperform Votes44765.26% Underperform Votes23834.74% Is IMNM or CHRS more profitable? Coherus BioSciences has a net margin of -0.15% compared to Immunome's net margin of -3,014.59%. Coherus BioSciences' return on equity of 0.00% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-3,014.59% -48.63% -41.62% Coherus BioSciences -0.15%N/A -24.44% Do analysts rate IMNM or CHRS? Immunome presently has a consensus price target of $28.83, indicating a potential upside of 139.88%. Coherus BioSciences has a consensus price target of $5.38, indicating a potential upside of 214.33%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do institutionals and insiders hold more shares of IMNM or CHRS? 44.6% of Immunome shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 8.6% of Immunome shares are owned by insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor IMNM or CHRS? In the previous week, Immunome had 2 more articles in the media than Coherus BioSciences. MarketBeat recorded 5 mentions for Immunome and 3 mentions for Coherus BioSciences. Immunome's average media sentiment score of 1.19 beat Coherus BioSciences' score of 1.12 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus BioSciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, IMNM or CHRS? Immunome has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Which has higher valuation & earnings, IMNM or CHRS? Immunome has higher earnings, but lower revenue than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$10.13M74.07-$106.81M-$8.11-1.48Coherus BioSciences$304.34M0.65-$237.89M-$0.08-21.38 SummaryImmunome beats Coherus BioSciences on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyA conspiracy Trump won’t unsealNew documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$197.01M$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-21.3846.24135.1817.53Price / Sales0.65440.311,235.42140.39Price / CashN/A182.1340.6537.95Price / Book-0.983.924.884.92Net Income-$237.89M-$42.03M$118.97M$225.78M7 Day Performance3.64%-3.37%16.19%-1.58%1 Month Performance118.87%7.95%16.02%6.67%1 Year Performance-15.76%21.00%34.95%22.48% Coherus BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus BioSciences4.2009 of 5 stars$1.71+0.6%$5.38+214.3%-21.2%$197.01M$304.34M-21.38246Short Interest ↓Positive NewsGap DownIMNMImmunome2.802 of 5 stars$12.44-1.1%$28.83+131.8%+59.4%$776.47M$10.13M-1.5540Short Interest ↓Positive NewsKROSKeros Therapeutics3.0723 of 5 stars$18.92+0.5%$81.33+329.9%-44.6%$766.39M$651,000.00-3.61100Analyst DowngradeHigh Trading VolumeKURAKura Oncology4.6093 of 5 stars$9.85+2.3%$29.38+198.2%-20.8%$765.94MN/A-4.08142TYRATyra Biosciences2.4681 of 5 stars$14.99+0.3%$31.00+106.8%+12.7%$758.49MN/A-9.2820Positive NewsCRONCronos Group2.3198 of 5 stars$1.94+0.3%$3.00+55.0%+1.0%$739.75M$87.24M-15.19356Short Interest ↓News CoveragePositive NewsERASErasca2.6376 of 5 stars$2.61+2.0%$5.90+126.1%+40.6%$737.92MN/A-3.08126Positive NewsGap UpEOLSEvolus3.9308 of 5 stars$11.53+0.2%$23.00+99.5%+18.5%$730.08M$202.09M-12.73170RAPPRapport Therapeutics1.8399 of 5 stars$19.70+5.0%$35.00+77.7%N/A$720.63MN/A0.00N/APositive NewsDNTHDianthus Therapeutics1.6579 of 5 stars$24.21+1.7%$46.43+91.8%+235.7%$716.62M$2.83M-9.5280Positive NewsAUTLAutolus Therapeutics2.8365 of 5 stars$2.62+5.2%$10.40+296.9%-50.3%$697.16M$1.70M-2.06330 Related Companies and Tools Related Companies Immunome Alternatives Keros Therapeutics Alternatives Kura Oncology Alternatives Tyra Biosciences Alternatives Cronos Group Alternatives Erasca Alternatives Evolus Alternatives Rapport Therapeutics Alternatives Dianthus Therapeutics Alternatives Autolus Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CHRS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRS Stock Alerts